Ken Griffin
AUTL

Ken Griffin’s Autolus Therapeutics AUTL Stock Holding History

Ken Griffin’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,300
Closed -$41.2K – 12633
2025
Q3 		$41.2K Sell
25,300
-3,400
-12% -$6.64K ﹤0.01% 12282
2025
Q2 		$65.4K Sell
28,700
-47,200
-62% -$78K ﹤0.01% 11631
2025
Q1 		$118K Buy
75,900
+48,700
+179% +$98.9K ﹤0.01% 11237
2024
Q4 		$63.9K Buy
27,200
+26,400
+3,300% +$89.2K ﹤0.01% 12107
2024
Q3 		$2.9K Sell
800
-2,100
-72% -$8.38K ﹤0.01% 13710
2024
Q2 		$10.1K Sell
2,900
-4,700
-62% -$20.3K ﹤0.01% 13108
2024
Q1 		$48.5K Buy
7,600
+4,300
+130% +$26.8K ﹤0.01% 12200
2023
Q4 		$21.3K Buy
+3,300
New +$12.6K ﹤0.01% 12572
2023
Q3 		– Sell
-7,000
Closed -$16.7K – 14260
2023
Q2 		$16.7K Sell
7,000
-300
-4% -$712 ﹤0.01% 12887
2023
Q1 		$13.4K Buy
7,300
+5,700
+356% +$11.1K ﹤0.01% 13365
2022
Q4 		$3.04K Buy
+1,600
New +$4.05K ﹤0.01% 14259
2022
Q1 		– Sell
-21,400
Closed -$111K – 13548
2021
Q4 		$111K Sell
21,400
-23,300
-52% -$140K ﹤0.01% 12612
2021
Q3 		$293K Buy
+44,700
New +$282K ﹤0.01% 11101

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ken Griffin's AUTL Position: Q1 2026 in Review

Ken Griffin reduced its Autolus Therapeutics (AUTL) stake by 60% in Q1 2026, selling an estimated $1.06M and leaving 459,404 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #8717.

Ken Griffin first reported a position in AUTL in Q2 2019 and has held it in 26 quarters since. The position peaked at $18.3M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Ken Griffin held 459,404 shares of Autolus Therapeutics worth $634K as of Q1 2026.
  • Ken Griffin sold 700,387 Autolus Therapeutics shares in Q1 2026, an estimated $1.06M.
  • Autolus Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8717 holding.
  • Ken Griffin first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • Ken Griffin's Autolus Therapeutics position peaked at $18.3M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.